Floatz logo

azd6738

HRD

Institute of Cancer Research, United KingdomPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the HRD cohort.

Asset / SponsorPhaseRating
Olaparib
Institute of Cancer Research, United Kingdom
Phase 2CCC
Durvalumab
Institute of Cancer Research, United Kingdom
Phase 2CCC
hwh340
Hubei Biological Medicine Industrial Technology Institute Co., Ltd.
Phase 1CC

Same molecule, other indications

azd6738 is also rated in:

small cell lung carcinomaDormant
B
Indicative ·
62 / 100
View asset →
squamous cell carcinomaDormant
B
Indicative ·
57 / 100
View asset →
adenocarcinomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →